Status:

COMPLETED

Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies

Lead Sponsor:

Insuline Medical Ltd.

Conditions:

Diabetes Mellitus, Insulin-Dependent

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

The study is a prospective, multi-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the ...

Detailed Description

Fifty five(55) type 1 IDDM subjects in three centers who use the MiniMed paradigm insulin pump, meeting the inclusion/exclusion criteria as outlined below and who provide written Informed Consent will...

Eligibility Criteria

Inclusion

  • Age between 18- 65 years old (including = 18 years and =65 years)
  • Gender: men and women
  • BMI: 18-35 kg/m2
  • Type 1 Insulin dependent diabetes using the MiniMed paradigm insulin pumps for at least six months and using insulin Lispro or Insulin Aspart.
  • Diabetic subjects with HbA1c values below 9.5% (including 9.5%).
  • Subject understands the study requirements and the treatment procedures and has signed an Informed Consent before any study-specific tests or procedures are performed
  • Subject is willing to comply with all specified follow-up evaluations -

Exclusion

  • Pregnancy
  • Breast feeding women.
  • Alcohol addiction
  • Had CABG (Coronary Artery Bypass Graft), are Post MI (Myocardial Infarction) or had active Ischemic heart disease prior to the study date
  • Had CVA (cardiovascular accident) or TIA (transient ischemic accident) prior to the study
  • Suffer from uncontrolled Hypertension (blood pressure in mm HG \>160 systolic or \> 95 diastolic)
  • Low blood hemoglobin concentration \<9 g/dL for female and \<11g/dL for male.
  • Abnormal kidney and/ or liver function tests. (If any of the liver or kidney function test parameters are greater than 3 fold normal values.
  • Subjects with Hyperthyroidism or Hypothyroidism with TSH level outside the normal range, TSH\>5.5 mIU/L or TSH\<0.4 mIU/L
  • Psychological incompetence
  • Any other clinical condition or history, that seems to be relevant to the principle investigator to disqualify the participant.
  • Subjects with diminished skin integrity
  • Subjects with heat sensitivity
  • Subjects involved in or planed to participate in other studies
  • Subjects using other drugs therapies to control blood glucose level other than insulin.

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT01216618

Start Date

October 1 2010

End Date

June 1 2011

Last Update

September 4 2014

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Mills-Peninsula Health Services

San Mateo, California, United States, 94401

2

Wolfson Medical Center

Holon, Israel

3

Haddasah Medical Organization

Jerusalem, Israel